Prognostic value and echocardiographic determinants of plasma myeloperoxidase levels in chronic heart failure.

[1]  K. Sunagawa,et al.  Overexpression of glutathione peroxidase attenuates myocardial remodeling and preserves diastolic function in diabetic heart. , 2006, American journal of physiology. Heart and circulatory physiology.

[2]  S. Hazen,et al.  Plasma myeloperoxidase levels in patients with chronic heart failure. , 2006, The American journal of cardiology.

[3]  B. Pathik,et al.  Myeloperoxidase and C-reactive protein augment the specificity of B-type natriuretic peptide in community screening for systolic heart failure. , 2006, American heart journal.

[4]  S. Hazen,et al.  Serum myeloperoxidase and mortality in maintenance hemodialysis patients. , 2006, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[5]  Ye Xiong,et al.  Attenuation of doxorubicin-induced contractile and mitochondrial dysfunction in mouse heart by cellular glutathione peroxidase. , 2006, Free radical biology & medicine.

[6]  A. Ducharme,et al.  Temporal increases in subclinical levels of inflammation are associated with adverse clinical outcomes in patients with left ventricular dysfunction. , 2006, Journal of cardiac failure.

[7]  K. Nagata,et al.  Pravastatin increases survival and suppresses an increase in myocardial matrix metalloproteinase activity in a rat model of heart failure. , 2006, Cardiovascular research.

[8]  E. Topol,et al.  Myeloperoxidase-Generated Oxidants Modulate Left Ventricular Remodeling but Not Infarct Size After Myocardial Infarction , 2005, Circulation.

[9]  S. Rajagopalan,et al.  Statin therapy is associated with improved cardiovascular outcomes and levels of inflammatory markers in patients with heart failure. , 2005, Journal of cardiac failure.

[10]  M. Lauer,et al.  Usefulness of tissue doppler and color M-mode indexes of left ventricular diastolic function in predicting outcomes in systolic left ventricular heart failure (from the ADEPT study). , 2005, The American journal of cardiology.

[11]  F. Recchia,et al.  Role of oxidative-nitrosative stress and downstream pathways in various forms of cardiomyopathy and heart failure. , 2005, Current vascular pharmacology.

[12]  A. Kumar,et al.  Statins downregulate myeloperoxidase gene expression in macrophages. , 2005, Biochemical and biophysical research communications.

[13]  Stuart D Katz,et al.  Vascular Endothelial Dysfunction and Mortality Risk in Patients With Chronic Heart Failure , 2005, Circulation.

[14]  J. Tu,et al.  Statin use and survival outcomes in elderly patients with heart failure. , 2005, Archives of internal medicine.

[15]  R. Tavendale,et al.  Sudden unexpected death in heart failure may be preceded by short term, intraindividual increases in inflammation and in autonomic dysfunction: a pilot study , 2004, Heart.

[16]  P. Mecocci,et al.  Increased F2 isoprostane plasma levels in patients with congestive heart failure are correlated with antioxidant status and disease severity. , 2004, Journal of cardiac failure.

[17]  Peter P. Liu,et al.  Elafin-overexpressing mice have improved cardiac function after myocardial infarction. , 2004, American journal of physiology. Heart and circulatory physiology.

[18]  D. Mozaffarian,et al.  Statin therapy is associated with lower mortality among patients with severe heart failure. , 2004, The American journal of cardiology.

[19]  J. Liao.  Statin Therapy for Cardiac Hypertrophy and Heart Failure , 2004, Journal of Investigative Medicine.

[20]  James D. Thomas,et al.  Plasma B-type natriuretic peptide levels in systolic heart failure: importance of left ventricular diastolic function and right ventricular systolic function. , 2004, Journal of the American College of Cardiology.

[21]  E. Topol,et al.  Prognostic value of myeloperoxidase in patients with chest pain. , 2003, The New England journal of medicine.

[22]  U. Ikeda,et al.  Increased urinary 15-F2t-isoprostane concentrations in patients with non-ischaemic congestive heart failure: a marker of oxidative stress , 2003, Heart.

[23]  K. Swedberg,et al.  Prognostic importance of the oxidized product of catecholamines, adrenolutin, in patients with severe heart failure. , 2003, American heart journal.

[24]  S. Hazen,et al.  Association of nitrotyrosine levels with cardiovascular disease and modulation by statin therapy. , 2003, JAMA.

[25]  P. Peeters,et al.  Cardiac troponin T and malondialdehyde modified plasma lipids in haemodialysis patients. , 2003, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[26]  Eric J. Topol,et al.  Myeloperoxidase and Plasminogen Activator Inhibitor 1 Play a Central Role in Ventricular Remodeling after Myocardial Infarction , 2003, The Journal of experimental medicine.

[27]  G. Fonarow,et al.  Statin therapy is associated with improved survival in ischemic and non-ischemic heart failure. , 2003, Journal of the American College of Cardiology.

[28]  A. Richards,et al.  Assay of brain natriuretic peptide (BNP) in human plasma: evidence for high molecular weight BNP as a major plasma component in heart failure. , 1993, The Journal of clinical endocrinology and metabolism.

[29]  K. Prasad,et al.  Increased chemiluminescence of polymorphonuclear leucocytes in dogs with volume overload heart failure. , 1989, British journal of experimental pathology.

[30]  K. Prasad,et al.  Increased Production of Oxygen Free Radicals by Polymorphonuclear Leukocytes in Heart Failure Due to Aortic Stenosis , 1989, Angiology.

[31]  Stanley L Hazen,et al.  ATVB in Focus Redox Mechanisms in Blood Vessels , 2005 .

[32]  S. Anker,et al.  Statins and the Role of Nitric Oxide in Chronic Heart Failure , 2004, Heart Failure Reviews.

[33]  筒井 崇.  Plasma oxidized low-density lipoprotein as a prognostic predictor in patients with chronic congestive heart failure , 2003 .

[34]  S. Hazen,et al.  Nitric oxide modulates the catalytic activity of myeloperoxidase. , 2000, The Journal of biological chemistry.